New Therapeutics for Heart Failure: Focusing on cGMP Signaling
Current drugs for treating heart failure (HF), for example, angiotensin II receptor blockers and β-blockers, possess specific target molecules involved in the regulation of the cardiac circulatory system. However, most clinically approved drugs are effective in the treatment of HF with reduced eject...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/16/12866 |
| _version_ | 1797584393798156288 |
|---|---|
| author | Supachoke Mangmool Ratchanee Duangrat Warisara Parichatikanond Hitoshi Kurose |
| author_facet | Supachoke Mangmool Ratchanee Duangrat Warisara Parichatikanond Hitoshi Kurose |
| author_sort | Supachoke Mangmool |
| collection | DOAJ |
| description | Current drugs for treating heart failure (HF), for example, angiotensin II receptor blockers and β-blockers, possess specific target molecules involved in the regulation of the cardiac circulatory system. However, most clinically approved drugs are effective in the treatment of HF with reduced ejection fraction (HFrEF). Novel drug classes, including angiotensin receptor blocker/neprilysin inhibitor (ARNI), sodium-glucose co-transporter-2 (SGLT2) inhibitor, hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker, soluble guanylyl cyclase (sGC) stimulator/activator, and cardiac myosin activator, have recently been introduced for HF intervention based on their proposed novel mechanisms. SGLT2 inhibitors have been shown to be effective not only for HFrEF but also for HF with preserved ejection fraction (HFpEF). In the myocardium, excess cyclic adenosine monophosphate (cAMP) stimulation has detrimental effects on HFrEF, whereas cyclic guanosine monophosphate (cGMP) signaling inhibits cAMP-mediated responses. Thus, molecules participating in cGMP signaling are promising targets of novel drugs for HF. In this review, we summarize molecular pathways of cGMP signaling and clinical trials of emerging drug classes targeting cGMP signaling in the treatment of HF. |
| first_indexed | 2024-03-10T23:52:17Z |
| format | Article |
| id | doaj.art-4c3c08c81be24494b3df5008f46e0913 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T23:52:17Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-4c3c08c81be24494b3df5008f46e09132023-11-19T01:31:07ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-08-0124161286610.3390/ijms241612866New Therapeutics for Heart Failure: Focusing on cGMP SignalingSupachoke Mangmool0Ratchanee Duangrat1Warisara Parichatikanond2Hitoshi Kurose3Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok 10400, ThailandDepartment of Pharmacology, Faculty of Science, Mahidol University, Bangkok 10400, ThailandDepartment of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok 10400, ThailandPharmacology for Life Sciences, Graduate School of Pharmaceutical Sciences, Tokushima University, Tokushima 770-8505, JapanCurrent drugs for treating heart failure (HF), for example, angiotensin II receptor blockers and β-blockers, possess specific target molecules involved in the regulation of the cardiac circulatory system. However, most clinically approved drugs are effective in the treatment of HF with reduced ejection fraction (HFrEF). Novel drug classes, including angiotensin receptor blocker/neprilysin inhibitor (ARNI), sodium-glucose co-transporter-2 (SGLT2) inhibitor, hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker, soluble guanylyl cyclase (sGC) stimulator/activator, and cardiac myosin activator, have recently been introduced for HF intervention based on their proposed novel mechanisms. SGLT2 inhibitors have been shown to be effective not only for HFrEF but also for HF with preserved ejection fraction (HFpEF). In the myocardium, excess cyclic adenosine monophosphate (cAMP) stimulation has detrimental effects on HFrEF, whereas cyclic guanosine monophosphate (cGMP) signaling inhibits cAMP-mediated responses. Thus, molecules participating in cGMP signaling are promising targets of novel drugs for HF. In this review, we summarize molecular pathways of cGMP signaling and clinical trials of emerging drug classes targeting cGMP signaling in the treatment of HF.https://www.mdpi.com/1422-0067/24/16/12866cyclic guanosine monophosphate (cGMP) signalingnatriuretic peptidessoluble guanylyl cyclase (sGC)heart failure (HF)drugs |
| spellingShingle | Supachoke Mangmool Ratchanee Duangrat Warisara Parichatikanond Hitoshi Kurose New Therapeutics for Heart Failure: Focusing on cGMP Signaling International Journal of Molecular Sciences cyclic guanosine monophosphate (cGMP) signaling natriuretic peptides soluble guanylyl cyclase (sGC) heart failure (HF) drugs |
| title | New Therapeutics for Heart Failure: Focusing on cGMP Signaling |
| title_full | New Therapeutics for Heart Failure: Focusing on cGMP Signaling |
| title_fullStr | New Therapeutics for Heart Failure: Focusing on cGMP Signaling |
| title_full_unstemmed | New Therapeutics for Heart Failure: Focusing on cGMP Signaling |
| title_short | New Therapeutics for Heart Failure: Focusing on cGMP Signaling |
| title_sort | new therapeutics for heart failure focusing on cgmp signaling |
| topic | cyclic guanosine monophosphate (cGMP) signaling natriuretic peptides soluble guanylyl cyclase (sGC) heart failure (HF) drugs |
| url | https://www.mdpi.com/1422-0067/24/16/12866 |
| work_keys_str_mv | AT supachokemangmool newtherapeuticsforheartfailurefocusingoncgmpsignaling AT ratchaneeduangrat newtherapeuticsforheartfailurefocusingoncgmpsignaling AT warisaraparichatikanond newtherapeuticsforheartfailurefocusingoncgmpsignaling AT hitoshikurose newtherapeuticsforheartfailurefocusingoncgmpsignaling |